Pazopanib Maintenance for SCLC

To evaluate the efficacy of pazopanib maintenance after 1st line CTx for SCLC.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

SCLC

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Samsung Medical Center

Seoul, 135-710, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

histologically confirmed SCLC
no disease progression after 4 cycles of etoposide/platinum 1st-line therapy
history of 4 cycles of etoposide/platinum 1st-line therapy
between 21 days and 42 days since C4D1 of etoposide/platinum
no symptomatic brain meta

Exclusion criteria

poor hepatic, renal function

Treatment and study plan

Pazopanib

Drug

Experimental

Other names: Votrient

Placebo

Drug

placebo arm

Primary outcomes

Progression-free survival

Time frame: 12 months

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Official study title

Phase II Study of Pazopanib Maintenance for SCLC

Important dates

Study start: 2013
Primary completion: 2017
Study completion: 2017
First posted: Feb 25, 2013
Registry last updated: Dec 9, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed